Speaker Profile

Ph.D., Population Health, Metabolon

Cindy builds partnerships with innovators to drive deep multi-omic phenotyping of multi-ethnic populations toward a future of real-time individualized healthcare. After completing her Ph.D. at UCSD, she joined Illumina as a Scientist where she founded their Consortia Program working in collaboration to build over 40 diverse array and sequencing-based tools in support of applications from psychiatric disease to advancing the global bovine dairy industry. She now leads population health initiatives in the western US for Metabolon. Cindy is an experienced consultant in the area of go-to-market strategy for startups and holds advisory board positions in several non-profits. She identifies strongly as a STEM mentor and coach for women in the sciences

Wellness & Aging Showcase:

Metabolon Inc is a health technology company advancing metabolomics for precision medicine for every area of life sciences research including applications in pharmaceutical research and development, clinical trials, nutrition, and consumer goods, and bioprocessing and cell culture science.

Metabolomics As A Functional Readout Of Wellness In The Context Of Polygenic Risk
Genetic insights have advanced our ability to stratify populations via polygenic risk. We discuss multi-omics and untargeted metabolomics as powerful tools to capture phenotype in the context of genetic risk. These tools guide researchers to advance preventative and individualized healthcare.

 Session Abstract – PMWC 2020 Silicon Valley

Track 6 - January 23 1.00 P.M.-4.30 P.M.

The PMWC 2020 Wellness & Aging Showcase will provide a 15-minute time slot for selected companies in Wellness and Aging to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from selected companies that build innovative solutions and harness the power of digital health, genomics, and data science with the goal to proactively prevent disease, maintain optimal health, and slow down aging.